News coverage about Amarin (NASDAQ:AMRN) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amarin earned a news sentiment score of 0.01 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.7158015655064 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of NASDAQ AMRN traded down $0.04 during mid-day trading on Friday, hitting $3.15. The company’s stock had a trading volume of 2,982,104 shares, compared to its average volume of 3,075,418. The firm has a market capitalization of $932.49 million, a PE ratio of -12.60 and a beta of 0.95. The company has a current ratio of 1.43, a quick ratio of 1.13 and a debt-to-equity ratio of -1.25. Amarin has a one year low of $2.35 and a one year high of $4.60.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $52.64 million for the quarter, compared to analysts’ expectations of $54.88 million. The business’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. equities research analysts anticipate that Amarin will post -0.42 earnings per share for the current fiscal year.
AMRN has been the topic of several research analyst reports. Cantor Fitzgerald set a $10.00 target price on Amarin and gave the stock a “buy” rating in a report on Wednesday, August 1st. Zacks Investment Research upgraded Amarin from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. ValuEngine upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. Finally, BidaskClub upgraded Amarin from a “sell” rating to a “hold” rating in a research report on Wednesday, May 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Amarin has an average rating of “Buy” and a consensus price target of $8.00.
In other news, General Counsel Joseph T. Kennedy sold 26,942 shares of Amarin stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $3.00, for a total transaction of $80,826.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.08% of the company’s stock.
Amarin Company Profile
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.